Gene Therapy Targeting Glaucoma: Where Are We?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In a chronic disease such as glaucoma, a therapy that provides a long lasting local effect, with minimal systemic side effects, while circumventing the issue of patient compliance, is very attractive. The field of gene therapy is growing rapidly and ocular applications are expanding. Our understanding of the molecular pathogenesis of glaucoma is leading to greater specificity in ocular tissue targeting. Improvements in gene delivery techniques, refinement of vector construction methods, and development of better animal models combine to bring this potential therapy closer to reality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In two separate clinical trials, research teams have reported partially restoring vision using gene therapy to treat advanced cases of LCA.(9,78)”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“In two separate clinical trials, research teams have reported partially restoring vision using gene therapy to treat advanced cases of LCA.(9,78)”
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078 · cited 3×
“They each have specific advantages and disadvantages to be considered in designing therapeutic strategies.(66)”
Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267 · cited 1×
“ERG responses confirmed the reversal of visual deficit.(13) These studies demonstrate that AAV vector holds great promise for treatment of retinal disorders such as LCA and provides useful information relevant to glaucoma gene therapy such as neuroprotection or rescue of glaucomatous optic nerve damage at an early sta…”
Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma
Steele, M. R., Inman, D. M., Calkins, D. J., Horner, P. J., & Vetter, M. L. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0865 · Cited by 196
Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160 · cited 1×
“Efficient gene delivery to photoreceptors and pigmented epithelial cells following subretinal injection of AAV has been achieved in various animal models.(30,45,47,94) AAV-mediated gene therapy slows photoreceptor loss in rodent models of primary photoreceptor diseases and in dogs with a naturally occurring disease si…”
Gene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149 · cited 1×
“Within 2 weeks of a single intravitreal virus injection, approximately 85% of rat RGCs were transduced.(81) Intravitreal injection of an AAV-2 vector encoding for a tetracycline (Tet)-regulated destabilized reporter gene, displayed sustained long-term regulation of the reporter gene in RGCs.”
Cited by
A novel cationic niosome formulation for gene delivery to the retina
Puras, G., Mashal, M., Zárate, J., Agirre, M., Ojeda, E., Grijalvo, S., Eritja, R., Diaz-Tahoces, A., Martínez Navarrete, G., Avilés-Trigueros, M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.004 · Cited by 164
Gene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Metadata
- Authors
- Liu, X., Rasmussen, C. A., Gabelt, B. T., Brandt, C. R., & Kaufman, P. L.
- Venue
- Survey of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 54
- Issue
- 4
- Pages
- 472-486
- ISSN
- 0039-6257 (ISSN-L)
- OpenAlex
- W1988929331
- Cited by
- 42
- References
- 7
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy Targeting Glaucoma: Where Are We? https://app.cochat.ai/papers/10.1016/j.survophthal.2009.04.003
- The paper
- Liu, X., Rasmussen, C. A., Gabelt, B. T., Brandt, C. R., & Kaufman, P. L. (2009). Gene Therapy Targeting Glaucoma: Where Are We? Survey of Ophthalmology. https://doi.org/10.1016/j.survophthal.2009.04.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.